Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03840343 · ClinicalTrials.gov registry record · Phase 1
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03840343: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT03840343 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03840343, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).
Interventions
- BIOLOGICAL Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose
- BIOLOGICAL Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2020-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03840343
The ClinicalTrials.gov registry entry for NCT03840343 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose is the first listed.
NCT03840343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03840343 about?
NCT03840343 is a clinical study titled "Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease". The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).
What is the current status of trial NCT03840343?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-10-23. Estimated completion is 2020-08-04.
What interventions are being tested in trial NCT03840343?
The interventions under investigation include: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose (BIOLOGICAL), Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT03840343?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.